Browse > Article
http://dx.doi.org/10.4014/jmb.1505.05020

Inhibition of Monoamine Oxidase by Anithiactins from Streptomyces sp.  

Lee, Hyun Woo (Department of Pharmacy, Sunchon National University)
Jung, Won Kyeong (Research Institute of Life Pharmaceutical Sciences, Sunchon National University)
Kim, Hee Jung (Department of Pharmacy, Sunchon National University)
Jeong, Yu Seok (Department of Pharmacy, Sunchon National University)
Nam, Sang-Jip (Department of Chemistry and Nano Science, Ewha Women’s University)
Kang, Heonjoong (Center for Marine Natural Products and Drug Discovery, School of Earth and Environmental Sciences, Seoul National University)
Kim, Hoon (Department of Pharmacy, Sunchon National University)
Publication Information
Journal of Microbiology and Biotechnology / v.25, no.9, 2015 , pp. 1425-1428 More about this Journal
Abstract
Monoamine oxidase (MAO) is found in most cell types and catalyzes the oxidation of monoamines. Three anithiactins (A-C, modified 2-phenylthiazoles) isolated from Streptomyces sp. were tested for inhibitory activity of two isoforms, MAO-A and MAO-B. Anithiactin A was effective and selective for the inhibition of MAO-A, with an IC50 value of 13.0 μM; however, it was not effective for the inhibition of MAO-B. Anithiactins B and C were weaker inhibitors for MAO-A and MAO-B. Anithiactin A was a reversible and competitive inhibitor for MAO-A with a Ki value of 1.84 μM. The hydrophobic methyl substituent in anithiactin A may play an important role in the inhibition of MAO-A. It is suggested that anithiactin A is a selective reversible inhibitor for MAO-A, with moderate potency, and can be considered a new potential lead compound for further development of novel reversible inhibitors for MAO-A.
Keywords
Anithiactin A; monoamine oxidase; Streptomyces sp.; selective inhibitor; competitive inhibitor;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Gentili F, Pizzinat N, Ordener C, Marchal-Victorion S, Maurel A, Hofmann R, et al. 2006. 3-[5-(4,5-Dihydro-1Himidazol-2-yl)-furan-2-yl]phenylamine (amifuraline), a promising reversible and selective peripheral MAO-A inhibitor. J. Med. Chem. 49: 5578-5586.   DOI
2 Kim H, Sablin SO, Ramsay RR. 1997. Inhibition of monoamine oxidase A by β-carboline derivatives. Arch. Biochem. Biophys. 337: 137-142.   DOI
3 Kim H, Yang I, Patil RS, Kang S, Lee J, Choi H, et al. 2014. Anithiactins AC, modified 2-phenylthiazoles from a mudflatderived Streptomyces sp. J. Nat. Prod. 77: 2716-2719.   DOI
4 Lin Z, Antemano RR, Hughen RW, Tianero MD, Peraud O, Haygood MG, et al. 2010. Pulicatins A-E, neuroactive thiazoline metabolites from cone snail-associated bacteria. J. Nat. Prod. 73: 1922-1926.   DOI
5 Lotufo-Neto F, Trivedi M, Thase ME. 1999. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 20: 226-247.   DOI
6 Malcomson T, Yelekci K, Borrello MT, Ganesan A, Semina E, De Kimpe N, et al. 2015. cis-Cyclopropylamines as mechanism-based inhibitors of monoamine oxidases. FEBS J. DOI: 10.1111/febs.13260 [Epub ahead of print].   DOI
7 Finberg JP. 2014. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol. Ther. 143: 133-152.   DOI
8 Fowler JS, Logan J, Azzaro AJ, Fielding RM, Zhu W, Poshusta AK, et al. 2010. Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAOA by CX157. Neuropsychopharmacology 35: 623-631.   DOI
9 Abdelhafez OM, Amin KM, Ali HI, Abdalla MM, Batran RZ. 2012. Synthesis of new 7-oxycoumarin derivatives as potent and selective monoamine oxidase A inhibitors. J. Med. Chem. 55: 10424-10436.   DOI
10 Bautista-Aguilera OM, Samadi A, Chioua M, Nikolic K, Filipic S, Agbaba D, et al. 2014. N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl) prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor. J. Med. Chem. 57: 10455-10463.   DOI
11 Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ. 1990. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br. J. Clin. Pharmacol. 30: 805-816.   DOI
12 Callebert J, Esteve JM, Hervé P, Peoc'h K, Tournois C, Drouet L, et al. 2006. Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine (2B) receptors in mice. J. Pharmacol. Exp. Ther. 317: 724-731.   DOI
13 Youdim MB, Edmondson D, Tipton KF. 2006. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 7: 295-309.   DOI
14 Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, Maroteaux L. 2008. Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J. Neurosci. 28: 2933-2940.   DOI
15 Fenical W, Jensen PR. 2006. Developing a new resource for drug discovery: marine actinomycete bacteria. Nat. Chem. Biol. 2: 666-673.   DOI
16 Ferino G, Vilar S, Matos MJ, Uriarte E, Cadoni E. 2012. Monoamine oxidase inhibitors: ten years of docking studies. Curr. Top. Med. Chem. 12: 2145-2162.   DOI
17 Mattsson C, Svensson P, Sonesson C. 2014. A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors. Eur. J. Med. Chem. 73: 177-186.   DOI
18 Moon K, Chung B, Shin Y, Rheingold AL, Moore CE, Park SJ, et al. 2015. Pentacyclic antibiotics from a tidal mud flatderived actinomycete. J. Nat. Prod. 78: 524-529.   DOI
19 Mostert S, Petzer A, Petzer JP. 2015. Indanones as high-potency reversible inhibitors of monoamine oxidase. ChemMedChem DOI: 10.1002/cmdc.201500059 [Epub ahead of print].   DOI
20 Pan HQ, Yu SY, Song CF, Wang N, Hua HM, Hu JC, Wang SJ. 2015. Identification and characterization of the antifungal substances of a novel Streptomyces cavourensis NA4. J. Microbiol. Biotechnol. 25: 353-357.   DOI
21 Parsons CG, Danysz W, Dekundy A, Pulte I. 2013. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox. Res. 24: 358-369.   DOI
22 Yang W, Dostal L, Rosazza JP. 1993. Aeruginol [2-(2’-hydroxyphenyl)-4-hydroxymethylthiazole], a new secondary metabolite from Pseudomonas aeruginosa. J. Nat. Prod. 56: 1993-1994.   DOI
23 Ramsay RR. 2012. Monoamine oxidases: the biochemistry of the proteins as targets in medicinal chemistry and drug discovery. Curr. Top. Med. Chem. 12: 2189-2209.   DOI
24 Ramsay RR. 2013. Inhibitor design for monoamine oxidases. Curr. Pharm. Des. 19: 2529-2539.   DOI
25 Stevens H, Brinkhoff T, Rink B, Vollmers J, Simon M. 2007. Diversity and abundance of gram positive bacteria in a tidal flat ecosystem. Environ. Microbiol. 9: 1810-1822.   DOI